Furthermore, Bray and colleagues studied the association of polymorphic variants of the ABCB1 and SLC22A16 genes with drug toxicity in breast cancer patients treated with DOX, and found that polymorphisms are associated with the development of toxicities [25]. This evidence concerns the gene SLC22A16 and breast cancer.